p-Cresol and cardiovascular risk in mild-to-moderate kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 7, 2010, Pages 1182-1189

  Meijers, Björn K I ^a   Claes, Kathleen ^a   Bammens, Bert ^a   De Loor, Henriette ^a   Viaene, Liesbeth ^a   Verbeke, Kristin ^b   Kuypers, Dirk ^a   Vanrenterghem, Yves ^a   Evenepoel, Pieter ^a  

^a Division of Nephrology   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PARA CRESOL; 4-CRESOL; BIOLOGICAL MARKER; CRESOL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; BELGIUM; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; KAPLAN MEIER METHOD; KIDNEY DISEASE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME;

AGED; BELGIUM; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CRESOLS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77954793132     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07971109     Document Type: Article

References (25)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van LF, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007 (Pubitemid 350074801)
2. Sarnak M, Levey A: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35 Suppl 1: s117-s131, 2000 (Pubitemid 30183825)
3. Foley R, Parfrey P, Sarnak M: The clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998 (Pubitemid 28527268)
4. Foley RN, Wang C, Collins AJ: Cardiovascular risk factor profiles and kidney function stage in the US general population: The NHANES III study. Mayo Clin Proc 80: 1270-1277, 2005 (Pubitemid 41395958)
5. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De MJ, Wetzels JF, Rosendaal FR, Dekker FW: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302: 1782-1789, 2009
6. Schiffrin EL, Lipman ML, Mann JFE: Chronic kidney disease: Effects on the cardiovascular system. Circulation 116: 85-97, 2007 (Pubitemid 47016250)
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu Cy: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
8. Wanner C, Krane V, Marz W, Olschewski M, Mann JFE, Ruf G, Ritz E, the German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
9. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F, the AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
10. Sarnak M, Coronado B, Greene T: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57: 327-335, 2002
11. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, HeimburgerO, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505-521, 2008
12. Meijers BKI, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P: Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73: 1173-1180, 2008
13. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4: 1551-1558, 2009
14. Meijers BK, Loor HD, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P: p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 4: 1932-1938, 2009
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen S, Kusek JW, Van Lente F, for the Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006
16. Martinez AW, Recht NS, Hostetter TH, Meyer TW: Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 16: 3430-3436, 2005
17. de Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K: Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 51: 1535-1538, 2005
18. de Loor H, Meijers BK, Meyer TW, Bammens B, Verbeke K, Dehaen W, Evenepoel P: Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A 1216: 4684-4688, 2009
19. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601-1610, 2003
20. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de ZD, Pocock S, van Veldhuisen DJ: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113: 671-678, 2006
21. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108: 2154-2169, 2003 (Pubitemid 37337595)
22. Meyer TW, Hostetter TH: Uremia. N Engl J Med 357: 1316-1325, 2007
23. Meijers BK, Van kerckhoven S, Verbeke k, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P: The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 54: 891-901, 2009
24. Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans ROB, Janssen WMT, Grobbee DE, de Jong PE, for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002
25. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112: 969-975, 2005 (Pubitemid 41170264)